전체 프로그램

ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,045 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

AntibodyLimited DatastaleJanssenApproved

ustekinumab (Stelara, 1: filgotinib 2: ustekinumab 3: vedolizumab 4: infliximab))

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#monoclonal-antibody#Janssen
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenApproved

ustekinumab (Stelara, 1: infliximab 2: filgotinib 3: ustekinumab 4: vedolizumab)

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#monoclonal-antibody#Janssen
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenApproved

ustekinumab (Stelara, 1: ustekinumab 2: vedolizumab 3: infliximab 4: filgotinib)

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#monoclonal-antibody#Janssen
Trials 1Status Recruiting
AntibodyLimited DatastaleJanssenApproved

ustekinumab (Stelara, 1: vedolizumab 2: infliximab 3: filgotinib 4: ustekinumab)

Ulcerative Colitis (UC) · Ulcerative Colitis (UC)

#UlcerativeColitisUC#Antibody#Approved#monoclonal-antibody#Janssen
Trials 1Status Recruiting
CGTLimited DatastaleCancer Research UKPhase 1

1RG-CART (1RG-CART)

Relapsed or Refractory Neuroblastoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
AntibodyLimited DatastaleCentre Leon BerardPhase 2

atezolizumab (Tecentriq, 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy)

Sarcoma,Soft Tissue · Sarcoma,Soft Tissue

#SarcomaSoftTissue#Antibody#Phase2#monoclonal-antibody#Sarcoma+2
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR19 and 4SCAR123 (4SCAR19 and 4SCAR123)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR19 and 4SCAR20 (4SCAR19 and 4SCAR20)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR19 and 4SCAR22 (4SCAR19 and 4SCAR22)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR19 and 4SCAR30 (4SCAR19 and 4SCAR30)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR19 and 4SCAR38 (4SCAR19 and 4SCAR38)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

4SCAR19 and 4SCAR70 (4SCAR19 and 4SCAR70)

B-cell Malignancies · B-cell Malignancies

#B-cellMalignancies#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
ADCLimited DatastaleThe Netherlands Cancer InstitutePhase 2

89Zr-Patritumab deruxtecan (89Zr-Patritumab deruxtecan)

Non-Small Cell Lung Carcinoma; Advanced Non-Small Cell Squamous Lung Cancer · EGFR

#EGFR#ADC#Phase2#antibody-drug-conjugate#Non-SmallCellLungCarcinoma+2
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, 89Zr-Pembrolizumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Merck
Trials 1Status Active
AntibodyLimited DatastaleJanssenPhase 2

daratumumab (Darzalex, 89Zr-daratumumab PET/CT)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#monoclonal-antibody#Janssen
Trials 1Status Active
AntibodyLimited DatastaleMaisonneuve-Rosemont HospitalPhase 2

Zevalin (90Y ibritumomab tiuxetan, 90Y ibritumomab tiuxetan (Zevalin))

Non-Hodgkins Lymphoma · Non-Hodgkins Lymphoma

#Non-HodgkinsLymphoma#Antibody#Phase2#monoclonal-antibody#Maisonneuve-Rosemont
Trials 1Status Active
CGTLimited DatastaleShanghai AbelZeta Ltd.Phase 1

A-CAR028 (A-CAR028)

Acute Myeloid Leukemia (AML); CAR-T Cell Therapy · Acute Myeloid Leukemia (AML)

#AcuteMyeloidLeukemiaAML#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
ADCLimited DatastaleJiangsu HengruiPhase 2

A2: SHR-A1811 with Camrelizumab with famitinib (A2: SHR-A1811 with Camrelizumab with famitinib)

Triple-negative Breast Cancer · Triple-negative Breast Cancer

#Triple-negativeBreastCancer#ADC#Phase2#antibody-drug-conjugate#Jiangsu
Trials 1Status Recruiting
CGTAAVLimited DatastaleMeiraGTx UK II LtdPreclinical

AAV OPTIRPE65 (AAV OPTIRPE65)

Leber Congenital Amaurosis (LCA); Eye Diseases · Leber Congenital Amaurosis (LCA)

#LeberCongenitalAmaurosisLCA#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTAAVLimited DatastaleREGENXBIO Inc.Phase 2

AAV directed hLDLR gene therapy (AAV directed hLDLR gene therapy)

Homozygous Familial Hypercholesterolemia (HoFH) · Homozygous Familial Hypercholesterolemia

#HomozygousFamilialHypercholester#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued

37 / 103 pages

← PreviousNext →